Heart Failure

 
ACP: Clyde Yancy, MD, MSc Reviews Advances in Heart Failure Research and Treatment
April 29, 2021

ACP: Clyde W Yancy, MD, gave a comprehensive update on a year's worth of pivotal science in treatment of heart failure. Here are the highlights.

Dapagliflozin Found Effective for HFrEF in Men and Women
March 31, 2021

In a subanalysis of the landmark DAPA-HF trial, dapagliflozin benefits were observed in both men and women, an important finding given variable response to cardiovascular drugs among women.

Semaglutide 2.4 mg Reduces Visceral Adiposity, Improves Lean Body Mass-to-Fat Mass Ratio
March 20, 2021

ENDO 2021: Obese individuals treated with semaglutide 2.4 mg vs placebo demonstrated improvements in body composition paralleling weight loss that may reduce risk for cardiometabolic disease.